secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0001437749-21-026154
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KemPharm Q3 net loss $0.05/sh; appoints Richard Pascoe as Executive Chairman
----------------------------------------------------------------------------

- Q3 2021 net loss $1.8M ($0.05 per basic share); revenue $2.0M (mostly service fees).
- Cash and equivalents $131.5M at Sep 30, 2021; 35.3M shares outstanding basic.
- Richard W. Pascoe appointed Executive Chairman, effective Nov 10, 2021.
- Pascoe receives $400K base salary, option for 100K shares with performance vesting.
- AZSTARYS commercial launch initiated Jul 21; >50M lives now have access per Corium.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774921026154/0001437749-21-026154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774921026154/kmph20210921_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-21-026154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer